Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genmab's zalutumumab fails Phase III trial in refractory head and neck cancer

This article was originally published in Scrip

Executive Summary

Genmab's experimental EGFR-targeted monoclonal antibody zalutumumab (HuMax-EGFr), one of its most advanced products in development, has failed to meet its primary overall survival endpoint in its first pivotal Phase III trial, in refractory head and neck cancer. Genmab shares fell by 20% on March 8th on the news.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts